The Role of Biopharmaceutics in Early Drug Development
We are dedicated to accelerating the development of new drugs for patients around the world. We provide CRO and CDMO services including formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry. These services are provided either individually or as an integrated service offering via our Translational Pharmaceutics® platform.
Quotient is your answer.
Quotient is your answer.
Quotient is your answer.
Quotient is your answer.
Quotient is your answer.
Our latest updates
News
A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials announced by Quotient Sciences and CytoAgents.
Exhibition
Schedule a partnering meeting at Biotech Showcase with our CSO, Peter Scholes and Senior Director of Business Development, Katie Stuart to share your drug development needs.
Case Studies
Druggability Technologies (DRGT) is developing DRGT-46 as a novel therapy for pain. Gabor Heltovics, CEO of DRGT, explains how Quotient Sciences enabled the rapid development, clinical assessment and commercial readiness of its DRGT- 46 product using integrated services across Quotient’s network of harmonized development and manufacturing sites in the UK and US.
Webinar
This webinar discusses effective strategies being used by biotech and pharmaceutical companies to overcome biopharmaceutic challenges for small molecules in today’s drug development pipeline; and explores alternative approaches for accelerating your early development plan.
Ask us a question
